

Product Data Sheet

Ebvaciclib

 Cat. No.:
 HY-114177

 CAS No.:
 2185857-97-8

 Molecular Formula:
 $C_{20}H_{27}F_2N_5O_4S$

Molecular Weight: 471.52

Target: CDK

Pathway: Cell Cycle/DNA Damage

Storage: Powder -20°C 3 years

In solvent

4°C 2 years -80°C 6 months

-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: 83.33 mg/mL (176.73 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1208 mL	10.6040 mL	21.2080 mL
	5 mM	0.4242 mL	2.1208 mL	4.2416 mL
	10 mM	0.2121 mL	1.0604 mL	2.1208 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline Solubility: ≥ 2.5 mg/mL (5.30 mM); Clear solution
- 2. Add each solvent one by one: 5% DMSO >> 95% (20% SBE- β -CD in saline) Solubility: \geq 2.5 mg/mL (5.30 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution
- 4. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: \geq 2.08 mg/mL (4.41 mM); Clear solution
- 5. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution
- 6. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution
- 7. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution
- 8. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: \geq 2.08 mg/mL (4.41 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with K_i values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity ^{[1][2]} .				
IC ₅₀ & Target	CDK2 0.09 nM (Ki)	CDK4 0.13 nM (Ki)	CDK6 0.16 nM (Ki)		
In Vitro	PF-06873600 (Example 8) is an orally bioavailable, cyclin-dependent kinase (CDK) inhibitor, with potential antineoplastic activity ^[1] . PF-06873600 selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. CDKs, ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation, are frequently overexpressed in tumor cells ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.				

CUSTOMER VALIDATION

- Br J Cancer. 2022 Sep 29.
- World J Surg Surgical Res. 2023 Jun 28.

See more customer validations on $\underline{www.MedChemExpress.com}$

REFERENCES

[1]. US 2018/0044344 A1.

[2]. NCI Drug Dictionary

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA